Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp – Safety Communication
Oncological, nephrological healthcare professionals and patients are notified by the US FDA and Amgen that all ESAs must be used under a REMS risk management program. FDA Alert on Erythropoiesis-Stimulating Agents (ESAs) FDA requires a REMS because studies have shown that ESAs (Procrit, Epogen and Aranesp) can increase the risk of tumor growth and shorten [...]
Read more
Recent Comments